USFDA issues warning letter to Brassica Pharma, Maharashtra

This USFDA Warning Letter serves as a reminder of the importance of strict CGMP compliance to ensure the safety and efficacy of medications.

The Health Master

July 28, 2024

245

Warning Letter Sign FDA USFDA — Warning Letter

Table of Contents

Last Updated on August 7, 2024 by The Health Master

Warning letter

This article details a recent U.S. Food and Drugs Administration (USFDA) Warning Letter issued to Brassica Pharma Pvt. Ltd., a drug manufacturer in India.

The letter outlines significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals, potentially jeopardizing the safety and sterility of their drugs.

Follow us on WhtasApp Channel

Key Findings of the USFDA Inspection

Data Integrity Lapses:

The USFDA discovered widespread fabrication of data in laboratory records, particularly concerning sterility testing.

This raises serious concerns about the accuracy and reliability of quality control measures.

Inadequate Sterility Testing:

Brassica Pharma failed to perform proper sterility testing on all drug product formulations, a critical step for ensuring aseptic processing. Additionally, their testing methods lacked proper validation.

Poor Aseptic Processing Practices:

The inspection revealed numerous instances of poor practices in the aseptic processing areas, such as operators touching sterile equipment and inadequate gowning procedures.

These lapses significantly increase the risk of contamination.

Deficient Facility Design:

The design of the aseptic processing lines and cleanroom layout was found to be inadequate, compromising sterile conditions.

Additionally, their environmental monitoring program lacked sufficient data to ensure product sterility.

Click for more Articles on Pharmaceuticals

Click for more Legal Articles on Pharmaceuticals

Potential Impact on Consumers

These violations pose a serious threat to consumer safety.

Improperly manufactured drugs could be contaminated with harmful bacteria, leading to infections and other health complications.

Brassica Pharma’s Response and Next Steps

The USFDA has demanded a comprehensive response from Brassica Pharma detailing their plan to address these deficiencies.

This includes:

A thorough investigation into the root cause of data integrity lapses and a plan to ensure accurate data recording in the future.
Implementation of a robust sterility testing program with validated methods.
Rigorous training for personnel on proper aseptic processing techniques and adherence to CGMP regulations.
Revamping the design of the aseptic processing areas to minimize contamination risks.
Engaging a qualified consultant to evaluate their operations and ensure CGMP compliance.

The USFDA has also placed Brassica Pharma on Import Alert 66-40, meaning their drugs cannot be imported into the United States until these violations are completely addressed.

Click for Guidance documents for industry

Consumer Takeaway

It’s crucial for consumers to be aware of such manufacturing issues.

If you take medications manufactured by Brassica Pharma, it’s important to stay informed about any recalls or updates related to their products.

This USFDA Warning Letter serves as a reminder of the importance of strict CGMP compliance to ensure the safety and efficacy of medications.

Note: This article is based on the information provided in the USFDA Warning Letter and does not constitute medical advice. If you have any concerns about your medications, please consult your doctor.

Click to read original warning letter

Disclaimer: This article contains information derived from the source mentioned below. Our team utilized an AI language model to rewrite and present the news or article in a unique format.